Antares Pharma Inc (NASDAQ:ATRS) Can’t Be More Risky. Short Interest Increased

October 2, 2018 - By Hugh Holland

Investors sentiment increased to 1.41 in Q2 2018. Its up 0.61, from 0.8 in 2018Q1. It increased, as 9 investors sold Antares Pharma, Inc. shares while 20 reduced holdings. 15 funds opened positions while 26 raised stakes. 59.50 million shares or 6.29% more from 55.98 million shares in 2018Q1 were reported.
Barclays Public Limited Co invested in 30,572 shares or 0% of the stock. Veritable Limited Partnership reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Jw Asset Management Limited Liability Co holds 1.82 million shares. Moreover, Aqr Capital Mgmt Limited Com has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). Brown Advisory Securities Llc holds 0.12% or 275,000 shares in its portfolio. Oppenheimer & Co has 25,600 shares for 0% of their portfolio. Grp Inc One Trading Lp invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). The California-based Hanson Mcclain has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Hightower Advsrs Limited Liability Company invested 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Tiaa Cref Invest Mngmt Ltd Llc invested in 0% or 315,629 shares. Moreover, Citadel Advsr Ltd Liability Corporation has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 37,720 shares. 2,507 are held by Piedmont Invest Advisors Lc. Us National Bank De reported 10,000 shares. Moreover, Metropolitan Life Ins New York has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 51,612 shares. Raymond James Fincl Serv Advsr owns 146,034 shares or 0% of their US portfolio.

Since May 9, 2018, it had 0 buys, and 13 selling transactions for $4.90 million activity. Another trade for 43,000 shares valued at $161,250 was sold by APPLE ROBERT F.

The stock of Antares Pharma Inc (NASDAQ:ATRS) registered an increase of 9.57% in short interest. ATRS’s total short interest was 6.33 million shares in October as published by FINRA. Its up 9.57% from 5.77M shares, reported previously. With 1.86M shares average volume, it will take short sellers 3 days to cover their ATRS’s short positions. The short interest to Antares Pharma Inc’s float is 4.77%.

The stock increased 17.48% or $0.57 during the last trading session, reaching $3.83. About 9.20 million shares traded or 606.65% up from the average. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 10.07% since October 2, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $602.98 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More notable recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Benzinga.com which released: “38 Stocks Moving In Tuesday’s Mid-Day Session” on October 02, 2018, also Fool.com with their article: “Here’s Why Antares Pharma Jumped Higher Today” published on October 02, 2018, Seekingalpha.com published: “FDA OKs Antares Pharm’s TRT med Xyosted” on October 01, 2018. More interesting news about Antares Pharma, Inc. (NASDAQ:ATRS) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on September 21, 2018 as well as Nasdaq.com‘s news article titled: “Antares Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference” with publication date: September 25, 2018.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>